PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Sees Significant Growth in Short Interest

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 26,800 shares, a growth of 82.3% from the February 28th total of 14,700 shares. Approximately 0.4% of the company’s stock are sold short. Based on an average daily volume of 17,700 shares, the days-to-cover ratio is presently 1.5 days.

PharmaCyte Biotech Stock Performance

NASDAQ PMCB traded down $0.06 during trading hours on Friday, reaching $1.32. 11,380 shares of the company’s stock were exchanged, compared to its average volume of 21,782. The company has a market capitalization of $9.06 million, a price-to-earnings ratio of 2.49 and a beta of -0.25. The company’s 50-day moving average is $1.63 and its two-hundred day moving average is $1.69. PharmaCyte Biotech has a one year low of $1.29 and a one year high of $2.55.

PharmaCyte Biotech (NASDAQ:PMCB) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.10) EPS for the quarter.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.